Intraperitoneal insulin infusion: on the way to the artificial pancreas
Creating an "artificial pancreas" (a "closed loop" insulin pump, with self-adjusting insulin abilities, based on real time continuous glucose monitoring data) – is one of the most actual medical challenges of modern engineering and cybernetics.Artificial pancreas (AP) prototypes...
Guardado en:
Autores principales: | , , , , |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/de55be4fd4da4e3eb7b2354f0b78b6a6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:de55be4fd4da4e3eb7b2354f0b78b6a6 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:de55be4fd4da4e3eb7b2354f0b78b6a62021-11-14T09:00:19ZIntraperitoneal insulin infusion: on the way to the artificial pancreas2072-03512072-037810.14341/DM2015332-45https://doaj.org/article/de55be4fd4da4e3eb7b2354f0b78b6a62015-10-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/7228https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Creating an "artificial pancreas" (a "closed loop" insulin pump, with self-adjusting insulin abilities, based on real time continuous glucose monitoring data) – is one of the most actual medical challenges of modern engineering and cybernetics.Artificial pancreas (AP) prototypes based on wearable insulin pump with subcutaneous insulin delivery are still problematic, mainly because of slow insulin pharmacokinetics. Intravenous insulin infusion via AP allows effectively maintain euglycaemia for inpatients, due to insulin pharmacokinetics and pharmacodynamics advantages. Unfortunately, it can’t be used for outpatients. Intraperitoneal insulin infusion is still relatively infrequently used in the world, but it is a promising alternative, compared to both previous methods due to a physiological action profile, fast insulin pharmacokinetics, relatively better safety and availability for outpatient usage.The purpose of this review is to describe the intraperitoneal insulin infusion features for diabetes patients at a point of AP creation perspectives.Vladimir Aleksandrovich Karpel'evElena Anatol'evna FedorovaYury Ivanovich PhilippovAleksandr Yur'evich MayorovMarina Vladimirovna ShestakovaEndocrinology Research Centrearticleinsulin pumpinsulinpharmacokineticsintraperitoneal infusiondiabetes mellitusartificial pancreasNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 18, Iss 3, Pp 32-45 (2015) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN RU |
topic |
insulin pump insulin pharmacokinetics intraperitoneal infusion diabetes mellitus artificial pancreas Nutritional diseases. Deficiency diseases RC620-627 |
spellingShingle |
insulin pump insulin pharmacokinetics intraperitoneal infusion diabetes mellitus artificial pancreas Nutritional diseases. Deficiency diseases RC620-627 Vladimir Aleksandrovich Karpel'ev Elena Anatol'evna Fedorova Yury Ivanovich Philippov Aleksandr Yur'evich Mayorov Marina Vladimirovna Shestakova Intraperitoneal insulin infusion: on the way to the artificial pancreas |
description |
Creating an "artificial pancreas" (a "closed loop" insulin pump, with self-adjusting insulin abilities, based on real time continuous glucose monitoring data) – is one of the most actual medical challenges of modern engineering and cybernetics.Artificial pancreas (AP) prototypes based on wearable insulin pump with subcutaneous insulin delivery are still problematic, mainly because of slow insulin pharmacokinetics. Intravenous insulin infusion via AP allows effectively maintain euglycaemia for inpatients, due to insulin pharmacokinetics and pharmacodynamics advantages. Unfortunately, it can’t be used for outpatients. Intraperitoneal insulin infusion is still relatively infrequently used in the world, but it is a promising alternative, compared to both previous methods due to a physiological action profile, fast insulin pharmacokinetics, relatively better safety and availability for outpatient usage.The purpose of this review is to describe the intraperitoneal insulin infusion features for diabetes patients at a point of AP creation perspectives. |
format |
article |
author |
Vladimir Aleksandrovich Karpel'ev Elena Anatol'evna Fedorova Yury Ivanovich Philippov Aleksandr Yur'evich Mayorov Marina Vladimirovna Shestakova |
author_facet |
Vladimir Aleksandrovich Karpel'ev Elena Anatol'evna Fedorova Yury Ivanovich Philippov Aleksandr Yur'evich Mayorov Marina Vladimirovna Shestakova |
author_sort |
Vladimir Aleksandrovich Karpel'ev |
title |
Intraperitoneal insulin infusion: on the way to the artificial pancreas |
title_short |
Intraperitoneal insulin infusion: on the way to the artificial pancreas |
title_full |
Intraperitoneal insulin infusion: on the way to the artificial pancreas |
title_fullStr |
Intraperitoneal insulin infusion: on the way to the artificial pancreas |
title_full_unstemmed |
Intraperitoneal insulin infusion: on the way to the artificial pancreas |
title_sort |
intraperitoneal insulin infusion: on the way to the artificial pancreas |
publisher |
Endocrinology Research Centre |
publishDate |
2015 |
url |
https://doaj.org/article/de55be4fd4da4e3eb7b2354f0b78b6a6 |
work_keys_str_mv |
AT vladimiraleksandrovichkarpelev intraperitonealinsulininfusiononthewaytotheartificialpancreas AT elenaanatolevnafedorova intraperitonealinsulininfusiononthewaytotheartificialpancreas AT yuryivanovichphilippov intraperitonealinsulininfusiononthewaytotheartificialpancreas AT aleksandryurevichmayorov intraperitonealinsulininfusiononthewaytotheartificialpancreas AT marinavladimirovnashestakova intraperitonealinsulininfusiononthewaytotheartificialpancreas |
_version_ |
1718429559420878848 |